Collegium Pharmaceutical Inc/ US19459J1043 /
31/07/2024 22:00:00 | Chg. -0.0300 | Volume | Bid01:42:26 | Ask01:42:26 | High | Low |
---|---|---|---|---|---|---|
38.5700USD | -0.08% | 809,265 Turnover: 20.65 mill. |
32.0000Bid Size: 100 | 40.8800Ask Size: 100 | 39.3200 | 38.1800 |
GlobeNewswire
13/06
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
GlobeNewswire
01/05
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer a...
GlobeNewswire
29/04
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® an...
GlobeNewswire
11/04
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes D...
GlobeNewswire
08/02
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
GlobeNewswire
24/10/2023
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
GlobeNewswire
10/10/2023
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
GlobeNewswire
24/08/2023
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026